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Influence of disodium etidronate on
Paget's disease of bone
H. G. MUIR, I. SCHABORT, F. S. HOUGH
Summary
The use of agents that decrease bone resorption,
notably the calcitonins, diphosphonates and
mithramycin, has been shown to result in symptomatic
and/or biochemical improvement in patients with
Paget's disease of bone (osteitis deformans). The
effects of short-term (6 months), low-dose (5 mg/kg
body mass/d) etidronate disodium, a diphosphonate
compound at present subject to registration in this
country, on the clinical and laboratory manifestations
of this disorder were examined. Marked symptomatic
improvement was noted in 70% of patients, while
biochemical parameters of bone turnover, namely
serum alkaline phosphatase level (44%) and urine
tlydroxyproline excretion (56%), decreased signifi-
cantly (P < 0,001). A technetium-99m bone scan
revealed an impressive reduction in uptake of isotope
in 50% of patients. The drug was well tolerated and
no adverse reactions (clinical, biochemical or haema-
tological) were evident It is concluded that short-
term low-dose etidronate disodium affords a con-
venient and effective therapeutic alternative in
patients with symptomatic Paget's disease.
S Atr Med J 1987; 72: 470-472.
Paget's disease of bone affects some 4 - 10% of patients over
the age of 45 years. I-3 The disease is highly prevalent in South
Africa and often presents in the asymptomatic patient as a
coincidental radiological finding. Usual symptoms include
localised bone pain, deformities, fractures and sensorineural
deafness; rarely high output cardiac failure, neurological
complications, immobilisation hypercalcaemia, hyperuricaemia
or sarcomatous degeneration of Pagetic lesions are observed. I-3
The radiological diagnosis of the disorder is usually apparent
- initial osteolytic disease secondary to increased bone resorp-
tion progresses to a mixed lytic-sclerotic phase which culmi-
nates in the typical sclerotic, expansive bone lesions that
characterise the disease. Although the condition is readily
diagnosed radiologicaliy, biochemical parameters (serum alka-
line phosphatase, serum osteocalcin and urinary hydroxyproline
excretion) and/or radio-isotope bone scanning are required to
assess activity of the disease.
Specific treatment is usually reserved for the symptomatic
patient. Therapeutic indications are, however, controversial
and clinical distinction between active disease and pain
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secondary to nerve entrapment or degenerative arthritis in
joints adjacent to involved bones, is often difficult. In South
Africa the hormone calcitonin still comprises the mainstay of
specific therapy. The calcitonins (porcine, salmon, eel, human)
have been shown to decrease the biochemical activity of the
disease, improve symptoms and induce healing of lytic bone
lesions. 3- s However, they require administration by injection
and not too infrequently cause intolerable nausea. 3-; The'
diphosphonates, a group of compounds related to inorganic
pyrophosphate, can be taken orally and have also been shown
to beneficially affect the symptomatic and biochemical features
of the disease.6- 9
This report summarises experience in the short-term use of
etidronate disodium (EHDP), a diphosphonate compound at
present subject to registration in this country.
Patients and methods
Ten patients (4 men) aged 39 - 70 years with severe symptomatic
Paget's disease were randomly selected for inclusion in the srudy.
A history of proven Paget's disease ranged from less than 3
months in 5 patients to many years in others (Table I). Monostotic
disease was present in 4 cases, with polyostotic involvement in the
rest. Four patients had a history of previous treatment with
salmon calcitonin, with little or no symptomatic improvement,
while the rest were either untreated or had received non-steroidal
anti-inflammatory agents only (Table I).
Patients were admitted to the Endocrine Unit of Tygerberg
Hospital, underwent a full clinical evaluation, which included a
detailed dietary history, and followed a standard diet (800 mg
calcium, 1000 mg phosphate, gelatin-free) for 3 days before
biochemical testing. Serum total calcium, phosphate, alkaline
phosphatase (AP), urea, creatinine, electrolytes and liver enzyme
levels were measured by routine Beckman auto-analytical tech-
niques, a full blood count was obtained, and 24-hour urinary
hydroxyproline excretion lO determined in each patient. All measure-
ments were done in duplicate on samples obtained on 2 consecutive
days. A radiological skeletal survey and technetium-99m bone
scan concluded the initial work-up.
Treatment with EHDP 5 mg/kg body mass/d, was initiated and
this regimen was maintained for 6 months. Patients were followed
up monthly to evaluate (I) clinical response (pain); (il) adverse
reactions; (iil) serum biochemistry; and (iv) haematology. After 6
months of therapy patients were readmitted to the unit and the
initial work-up was repeated.
Results
Of the 10 subjects treated with EHDP 7 had a very satisfactory
symptomatic response and were virtually pain-free after 6 months
of therapy. Three patients experienced minimal to no improvement
(Table I). No adverse reactions were experienced by any of the
patients anE! no subject reported an exacerbation of bone pain.
A decrease in serum total AP level was apparent in all patients
studied. The mean serum AP level for the group decreased by an
average 44% after 6 months of therapy; this was most noticeable
within the first 3 months after which serum levels tended to
stabilise (Fig. 1). Moreover, a good correlation between clinical
improvement and biochemical response was noted. Similarly,
urinary hydroxyproline excretion decreased by an average 56%
after 6 months of therapy (Table II). The isotope bone scan was
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Patient
No.
1
2
3
4
5
6
7
8
9
10
Age
(yrs)
70
66
70
69
59
63
70
70
39
54
TABLE I. STUDY POPULATION
Duration Skeletal
Sex (mo.) involvement
M 1 P
M 15 P
F 16 M
F 72 P
F 1 P
F 1 P
M 3 P
F 20 M
M 2 M
F 41 M
Previous
therapy
None
SCT
SCT
None
None
None
None
SCT
None
SCT
Response
to EHDP
Good
Good
Good
Good
Good
Good
Good
Poor
Poor
Poor
P = polyostotic; M = monostotic; SeT = salmon calcitonin.
* P< 0,05 comparing values before and after EHDP.
..P< 0,001 comparing values before and after EHDP.
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230,00 ± 26,00**
2,35 ± 0,05
1,21 ±0,10*
87,00 ± 6,00
5,40 ± 0,70
10,00 ± 1,40
20,OO± 4,00
19,00 ± 6,00
19,00 ± 9,00
135,00 ± 5,00
6,10 ± 0,50
267,00 ± 21,00
502 ± 69,00 221,00 ± 59,00**
412,00 ± 20,00
2,36 ± 0,05
0,91 ± 0,10
82,00 ± 5,00
4,70 ± 0,60
8,00 ± 1,20
25,00 ± 4,00
19,00 ± 5,00
19,00 ± 6,00
138,00 ± 4,00
6,30 ± 0,60
301,00 ± 38,00
TABLE 11. INFLUENCE OF EHDP ON SERUM AND URINE
PARAMETERS (MEAN ± SEM)
Before EHDP After EHDPParameter
Serum
Alkaline phosphatase
(lUll)
Total calcium (mmol/I)
Phosphate (mmolll)
Creatinine (umolll)
Urea (mmolll)
Total bilirubin (Ilmolll)
AST (UII)
ALT (UII)
GGT (UII)
Haemoglobin. (gll)
Leucocytes (103 /1l1)
Platelets (109 /1)
Urine
Hydroxyproline
(Ilmol/m2/d)
unchanged in the 3 clinical non-responders, improved marginally
in 2 subjects, and revealed a marked reduction in uptake in the
remaining 5 patients.
The radiological survey, blood count, serum urea and creatinine
levels and liver function profile were unchanged after 6 months of
EHDP treatment (Table II). Similarly, the serum total calcium
was unaltered, but the serum phosphate increased marginally,
albeit significantly, on therapy (Table II).
Discussion
Before 1970, no safe and effective drug therapy for Paget's
disease was available. Today at least three main medical
treatments - the calcitonins, the diphosphonates and
mithramycin - have been shown to cause symptomatic, bio-
chemical, histological and/or radiological improvement. All
these drugs are primarily inhibitors of bone resorption and
their ingestion results in a rapid decrease in urinary hydroxy-
proline excretion (a parameter of bone resorption), followed by
a decrease in serum AP levels (an index of bone formation). I-3
Bone pain is the main indication for drug therapy. However,
the presence of local (e.g. nerve entrapment syndromes) or
systemic (e.g. immobilisation hypercalcaemia, cardiac failure)
complications or severe progressive disease especially in young
patients, even if asymptomatic, should also be considered as
o 1 234 5 6
Duration of therapy (months)
Fig. 1. Effect of EHDP on serum alkaline phosphatase levels in 10
patients with Paget's disease. Values (mean ± SEM) are shown
at monthly intervals after the start of EHDP therapy.
possible indications for treatment. 1-8,1 1,12 Since drug therapy is
known to diminish bone turnover and blood flow, and appears
to prevent excessive haemorrhage and postoperative hypercal-
caemia, preparation for major orthopaedic surgery should be
regarded as yet another potential indication. 13
The calcitonins are very effective in alleviating symptoms
and improving the biochemical and histological parameters of
the disease.1-s,11 These drugs are, however, expensive, require
administration by injection, and commonly cause nausea, flush-
ing, gastro-intestinal intolerance and a metallic taste sensa-
tion.3-5 In some patients antibody-mediated resistance to the
drug develops although responsiveness is usually restored by
use of a calcitonin derived from another species. The major
problem with calcitonin therapy is, however, a biochemicaV
symptomatic relapse shortly after stopping treatment, suggest-
ing incomplete suppression of disease and implying that long-
term therapY with this agent 'may be needed in some
patients. 4,s,1 Weekly infusions of mithramycin, a cytotoxic
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antibiotic, is very effective in rapidly improving bone pain,
and markedly decreases bone turnover in patients with severe
Paget's disease. ll Renal, bone marrow and hepatic toxicity,
however, makes this drug less than ideal as first choice in the
treatment of Paget's disease. 12
Several diphosphonates have proved useful in the treatment
of Paget's disease. 6- 9 EHDP is administered orally, although
absorption from the gut is only I - 10% of an oral dose, being
highest when the drug is not taken with food. 6 The effect of
EHDP on biochemical and histological parameters of the
disease is evident at doses of 2,5 - 20 mg/kg body mass/d.6- 8
At doses of 10 - 20 mg/kg/d greater suppression of bone
turnover is usually achieved with EHDP than with calcitonin.6
Also, acquired resistance to treatment is absent and maintenance
of suppression after stopping treatment is prolonged, often for
several years. 8,9,14 The nature and length of remission is partly
related to the severity of the disease, to drug dosage and to
treatment duration.9 On average, some 60% of patients exhibit
symptomatic relief, while biochemical parameters decrease by
approximately 50% after 6 months of low-dose (5 mg/kg)
EHDP treatment. 6- 9 Similar results were obtained in the
present study, although 4 of our 10 patients had previously
responded poorly to treatment with salmon calcitonin. Although
small patient numbers do not allow firm conclusions to be
drawn, it is interesting to note that while 6 of the 7 patients
who responded to therapy had polyostotic involvement, all 3
non-responders had monostotic disease.
Adverse reactions are also partly dose-related and include
diarrhoea, a rise in serum AP levels secondary to increased
renal tubular reabsorption of phosphate, and in 1 - 10% of
patients, the de novo development of pain in affected bones
during the first few months of treatment. I- 3,6-9 No gastro-
intestinal side-effects or exacerbation of bone pain were noted
in the present study which employed an EHDP dose of
5 mg/kg/d, although the mean serum AP levels did increase
marginally after 6 months of therapy. This change in AP
homeostasis is, however, not associated with any known adverse
effecis.2The most serious potential complication of diphospho-
nate therapy comprises the development of a mineralisation
defect and the possibility of an increased propensity to spon-
taneous fractures. 6- 9,15-17 Most clinical studies have confirmed
that the 5 mg/kg/d dose is seldom if ever associated with
impaired mineralisation,6-9,15 although a recent report by Boyce
er al. 17 documented histological evidence of focal osteomalacia
in 9 of 13 patients recei'ling 5 - 8 mg EHDP/kg/d. The agent
dichloromethylene diphosphonate (C12 MDP) is also an
extremely potent inhibitor of bone resorption, but unlike
EHDP has a much weaker effect on inhibiting bone minerali-
sation.2 Although the evidence for radiological healing of
osteolytic lesions with EHDP is less compelling than reports
of clear regression of bone lesions after treatment with calci-
tonin,18 large controlled clinical trials have provided no objective
evidence of an increased fracture rate if treatment with EHDP
does not exceed 6 months. 6- 9,15
We conclude that the diphosphonate EHDP affords a con-
venient and most effective therapeutic alternative to the cal-
citonins in patients with symptomatic Paget's disease of bone.
It is suggested that the drug be administered in a dose of
5 mg/kg/d for 4 - 6 months. Regular follow-up and close
biochemical monitoring, preferably by physicians versed in the
managemen~ of patients with metabolic bone disease, are
necessary. Because of the potential development of mineralisa-
tion defects, it is probably not justified to advocate the use of
higher dose regimens and/or longer treatment periods, parti-
cularly for patients with lytic lesions in weight-bearing bones,
until the optimum dose and duration of therapy have been
established.
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